Assessing the proportion of patients with type 2 diabetes in tertiary care eligible for combination therapy with GLP-1 receptor agonist and SGLT2 inhibitors

20260 citationsJournal Articlehybrid Open Access

Authors

The current study received unrestricted support from AstraZeneca.

Good health and well-being

Published in: European Journal of Internal Medicine

Field-Weighted Citation Impact: 0.00